CompletedPhase 3NCT02410772

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Studying Primary pulmonary tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centers for Disease Control and Prevention
Principal Investigator
Susan Dorman, MD
Medical University of South Carolina
Intervention
rifapentine(drug)
Enrollment
2516 enrolled
Eligibility
12 years · All sexes
Timeline
20162021

Study locations (30)

Collaborators

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02410772 on ClinicalTrials.gov

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary pulmonary tuberculosis

← Back to all trials